An immune reaction may be necessary for cancer development

Theoretical Biology and Medical Modelling

Volumn 3, Issue , 2006, Pages

  Prehn, Richmond T ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CARCINOGENESIS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSURVEILLANCE; NONHUMAN; ONCOGENE; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; BIOLOGICAL MODEL; CANCER TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; EDITORIAL; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; IMMUNOCOMPETENCE; IMMUNOLOGY; ISOGRAFT; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; MOUSE MUTANT; NEOPLASM; NUDE MOUSE; PATHOGENICITY; RETROVIRUS INFECTION; VIRUS INFECTION;

ANIMALIA;

3 METHYLCHOLANTHRENE; CARCINOGEN;

ANIMALS; CARCINOGENS; FEMALE; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; METHYLCHOLANTHRENE; MICE; MICE, NUDE; MICE, SCID; MODELS, IMMUNOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RETROVIRIDAE INFECTIONS; TRANSPLANTATION, ISOGENEIC; TUMOR VIRUS INFECTIONS;

EID: 33646360823     PISSN: 17424682     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-3-6     Document Type: Review

References (61)

1. Prehn RT, Main JM: Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957, 18:769-778.
2. Prehn RT: Relationship of tumor immunogenicity to concentration of the oncogen. J Natl Cancer Inst 1975, 55:189-190.
3. Lawler EM, Prehn RT: Influence of immune status of host on immunogenicity of tumors induced with two doses of methylcholanthrene. Cancer Immunol Immunother 1982, 13:194-197.
4. Carbone G, Borrello MG, Molla A, Rizzetti MG, Pierotti MA, Della Porta G, Parmiani G: Activation of ras oncogenes and expression of tumor- specific transplantation antigens in methylcholanthrene-induced murine fibrosarcomas. Int J Cancer 1991, 47:619-625.
5. Prehn RT: Analysis of antigenic heterogeneity within individual 3-methylcholanthrene- induced mouse sarcomas. J Natl Cancer Inst 1970, 45:1039-1045.
6. Bartlett GL: Effect of host immunity on the antigenic strength of primary tumors. J Natl Cancer Inst 1972, 49:495-504.
7. Bubenik J, Adamcova B, Koldovsky P: Changes in the antigenicity of tumors passaged against immunoselective pressure. In Genetic Variations in Somatic Cells Edited by: Klein J, Votiskova M, Zeleny V. Prague: Acad Publ House; 1967:405-408.
8. Globerson A, Feldman M: Antigenic specificity of benzo(a)pyrene-induced sarcomas. J Natl Cancer Inst 1964, 32:1229-1243.
9. Prehn RT: Perspectives on oncogenesis: Does immunity stimulate or inhibit neoplasia? J Reticuloendothel Soc 1971, 10:1-16.
10. Prehn RT, Lappé MA: An immunostimulation theory of tumor development. Transplant Rev 1971, 7:26-54.
11. Prehn RT: The immune reaction as a stimulator of tumor growth. Science 1972, 176:170-171.
12. Prehn LM: Immunostimulation of highly immunogenictarget tumor cells by lymphoid cells in vitro. J Natl Cancer Inst 1976, 56:833-838.
13. Prehn RT: Stimulatory effects of immune reactions upon the growths of untransplanted tumors. Cancer Res 1994, 54:908-914.
14. Jeejeebhoy HF: Stimulation of tumor growth by the immune response. Int J Cancer 1974, 13:665-678.
15. Klein G, Sjögren HO, Klein E, Hellström KE: Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960, 20:1561-1572.
16. Stjernswärd J: Immune status of the primary host toward its own methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1968, 40:13-22.
17. Basombrio MA, Prehn RT: Immune status of autochthonous and adoptively protected mice toward spontaneous and chemically induced tumors. Cancer Res 1972, 32:2545-2550.
18. Willimsky G, Blankenstein T: Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005, 437:141-146.
19. Prehn RT, Bartlett GL: Surveillance, latency, and the two levels of MCA-induced tumor immunogenicity. Int J Cancer 1987, 39:106-110.
20. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
21. Burnet FM: Immunological surveillance in neoplasia. Transpl Rev 1971, 7:3-25.
22. Prehn RT: Immunostimulation of chemical oncogenesis in the mouse. Int J Cancer 1977, 20:918-922.
23. Prehn LM, Lawler EM: Rank order of sarcoma susceptibility among mouse strains reverses with low concentrations of carcinogen. Science 1979, 204:309-310.
24. Prehn LM, Lawler EM: The immune basis of dosage-induced reversal of the rank-order of strain susceptibility to MCA. Int J Cancer 1987, 39:240-243.
25. Bernfeld P, Homburger F: Tumor susceptibility in two mouse strains with varying doses of carcinogen. Proc Soc Exp Biol Med 1982, 170:39-41.
26. Stutman O: Immunodepression and malignancy. Adv Cancer Res 1975, 22:261-422.
27. Martinez C: Effect of early thymectomy on development of mammary tumours in mice. Nature 1964, 203:1188-1188.
28. Johnson S: Effect of thymectomy on the induction of skin tumours by dibenzanthracine and of breast tumours by dimethylbenzanthracine in mice of the IF strain. Br J Cancer 1968, 22:755-761.
29. Prehn LM, Kojima A: Paradoxical effect of three- day thymectomy on sarcogenesis in the mouse with different dosages of methylcholanthrene. Cancer Res 1986, 46:4971-4976.
30. Outzen HC: Development of carcinogen-induced skin tumors in mice with varied states of immune capacity. Int J Cancer 1980, 26:87-92.
31. Ryan WL, Curtis GL, Heidrick ML, Stenback F: Autoantibody and tumor promotion. Proc Soc Exp Biol Med 1980, 163:212-215.
32. Murasko DM, Prehn RT: Stimulatory effect of immunization on tumor induction by Moloney murine sarcoma virus. J Natl Cancer Inst 1978, 61:1323-1327.
33. Chai CK: Hyperplastic growth in skin grafts of rabbits. J Hered 1982, 73:304-304.
34. Hewett HB, Blake ER, Walder AS: A critique of the evidence for active host defenses against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 1976, 33:241-259.
35. Schreiber RD: Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. Cancer Immunity 2005:1-14.
36. Leidner RS, Aboulafia DM: Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005, 19:635-644.
37. Penn I: Tumors in the immunocompromised patient. Annu Rev Med 1988, 39:63-73.
38. Stewart THM: Evidence for immune facilitation of breast cancer growth and for the immune promotion of oncogenesis in breast cancer. Medicina (Buenos Aires) 1996, 56:13-24.
39. Stewart THM: Reduced incidence of rectal cancer, compared to gastric and colonic cancer. Clin Cancer Res 1997, 3:51-55.
40. Engel AM, Svane IM, Ryard J, Werdelin O: MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol 1997, 45:463-470.
41. Svane IM, Boesen M, Engel AM: The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors-lessons from normal and immunodeficient mice. Med Oncol 1999, 4:223-238.
42. Prehn LM, Outzen HC: Primary tumor immunity in nude mice. Int J Cancer 1977, 19:688-691.
43. Carbone G, Parmiani G: Increased oncogenic effect of a low dose of methylcholanthrene in immunodepressed mice. Tumori 1971, 57:225-231.
44. Gershwin ME, Ikeda R: DMBA induced papillomas in congenitally athymic (nude) and hereditarily asplenic (Dh/+) mice: contrasts and comparisons with immunologically intact littermates. Develop Comp Immunol 1978, 2:529-538.
45. Giovanella BC, Stehlin JS Jr, Williams LJ Jr, Lee SS, Shepard RC: Heterotransplantation of human cancers into nude mice; a model system for human cancer chemotherapy. Cancer 1978, 42:2269-2281.
46. Molthoff CFM, Calame JJ, Pinedo HM, Boven E: Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int J Cancer 1991, 47:72-79.
47. Houghton JA, Taylor DM: Maintenance of biological and biochemical characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br J Cancer 1978, 37:119-212.
48. Roholl PJ, Rutgers GH, Rademakers LH, De Wager RA, Elbers JR, Van Unnik: Characterization of human soft tissue sarcomas in nude mice. Evidence for histogenic properties of malignant fibrous histiocytomas. Am J Pathol 1988, 131:559-568.
49. Hammond WG, Benfeld JR, Tesluk H, Johnson JR, Teplitz RL: Tumor progression by lung cancers growing in hosts of different immunocompetence. Cancer J 1995, 8:130-138.
50. de Visser KE, Korets LV, Coussens LM: De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7:411-423.
51. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D: Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 2003, 197:1017-1028.
52. Prehn RT: Infection may have shaped the evolution of the biphasic immune response to cancer. Folia Biologica 1987, 43:131-132.
53. Marchant J: Sarcoma induction in mice by methylcholanthrene (Antigenicity tests of sarcomas induced in thymus grafted and control animals). Br J Cancer 1969, 23:383-390.
54. Sonnenschein C, Soto A: The Society of Cells. Oxford: BIOS Scientific Publishers; 1999.
55. Osgood EE: A unifying concept of the etiology of the leukemias, lymphomas, and cancers. J Natl Cancer Inst 1957, 18:155-166.
56. Bullough WS, Laurence EB, Iverson OH, Elgjo K: The vertebrate epidermal chalone. Nature 1967, 214:578-580.
57. Michiel DF, Oppenheim JJ: Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol 1992, 3:3-15.
58. Mantovani A, Bottazzi B, Colatta F, Sozzani S, Ruco I: The origin and function of tumor-associated macrophages. Immunol Today 1992, 13:265-270.
59. Tsai SJ, Loeffler DA, Heppner GL: Associated effects of bromocriptine on neoplastic progression of mouse mammary preneoplastic hyperplastic alveolar nodule line C4 and on hyperplastic alveolar nodule-infiltrating and splenic lymphocyte function. Cancer Res 1992, 52:2209-2215.
60. Konger RL, Chan THC: Epidermal growth factor induces terminal differentiation in human epidermoid carcinoma cells. J Cellular Physiol 1993, 156:515-521.
61. Montavani A: Inflammation by remote control. Nature 2005, 435:752-753.